Last reviewed · How we verify
Tnkase (TENECTEPLASE)
Tenecteplase binds to fibrin and converts plasminogen to plasmin, enhancing fibrin-specific plasmin generation.
Tnkase (Tenecteplase) is a recombinant plasminogen activator developed by Genentech, currently owned by the same company. It works by targeting plasminogen to activate plasmin, which breaks down blood clots. Tnkase is approved for treating acute myocardial infarction and ankylosing spondylitis, with FDA approval in 2000. The commercial status of Tnkase is patented, and its safety considerations include the risk of bleeding and thrombocytopenia. As a recombinant protein, Tnkase's mechanism of action is complex, but it ultimately aims to restore blood flow by dissolving clots.
At a glance
| Generic name | TENECTEPLASE |
|---|---|
| Sponsor | Roche |
| Target | fibrin |
| Modality | Enzyme |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2000 |
Mechanism of action
Tenecteplase is a modified version of tPA that specifically binds to fibrin, which helps convert plasminogen to plasmin more efficiently in the presence of fibrin. This specificity reduces the systemic activation of plasminogen and the degradation of circulating fibrinogen compared to non-fibrin-specific molecules.
Approved indications
- Acute myocardial infarction
- Ankylosing spondylitis
Common side effects
- Cerebral haemorrhage
- No adverse event
- Haemorrhage intracranial
- Neurological decompensation
- Haemorrhagic transformation stroke
- Wrong product administered
- Cerebral infarction
- Ischaemic stroke
- Cerebral haematoma
Key clinical trials
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO) (PHASE3)
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tnkase CI brief — competitive landscape report
- Tnkase updates RSS · CI watch RSS
- Roche portfolio CI